Therapiemöglichkeiten der Alzheimer-Krankheit durch passive Immunisierung mit dem NT4X-Antikörper im Tg4-42hom-Mausmodell

Borgers, Henning

dc.contributor.advisor	Bayer, Thomas A. Prof. Dr.
dc.contributor.author	Borgers, Henning
dc.date.accessioned	2017-07-05T08:50:02Z
dc.date.available	2017-07-11T22:50:06Z
dc.date.issued	2017-07-05
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0023-3E99-8
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-6363
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc	610	de
dc.title	Therapiemöglichkeiten der Alzheimer-Krankheit durch passive Immunisierung mit dem NT4X-Antikörper im Tg4-42hom-Mausmodell	de
dc.type	doctoralThesis	de
dc.title.translated	Alzheimer therapy with passive immunization using the antibody NT4X in Tg4-42hom mice	de
dc.contributor.referee	Dresbach, Thomas Prof. Dr.
dc.date.examination	2017-07-04
dc.description.abstracteng	Aβ4-42 is one of the major variants of beta-amyloid (Aβ) in the Alzheimer brain and one of the earliest to appear in the development of the disease. It shows an increased aggregation tendency and toxicity. Furthermore it has been shown previously, that Aβ4-42 also affects brain functions and induces cognitive impairments in vivo after intraventricular injection to the brain of wildtype mice and in Tg4-42 mice. These mice carry a transgene for an enhanced expression of Aβ4-42 and develop a severe neuron loss in the CA1 region of the hippocampus that correlates with age-dependent memory deficits. Nevertheless, Aβ4-42 has not been considered as a therapeutic target yet. This study analyzes the progression of cognitive deficits in the brain of Tg4-42 mice to detect the best time to start a treatment. It then demonstrates that passive immunization with the antibody NT4X reacting with the free N-terminus of Aβ4-x and AβpE3-X but not with Aβ1-x significantly attenuates neuron loss in the hippocampus of Tg4-42 mice and rescues spatial reference memory deficits. For the first time it could be demonstrated that a preventive therapy with NT4X, which has previously been proven to rescue the toxicity of oligomeric Aβ4-42 in vitro, has therapeutically beneficial effects in an Alzheimer mouse model in vivo, which emphasizes the meaning of Aβ4-42 as a possible target in the treatment of Alzheimer’s disease.	de
dc.contributor.coReferee	Oppermann, Martin Prof. Dr.
dc.subject.ger	Alzheimer	de
dc.subject.ger	Passive Immunisierung	de
dc.subject.ger	NT4X	de
dc.subject.ger	Tg4-42	de
dc.subject.ger	CA1	de
dc.subject.ger	Nervenzellverlust	de
dc.subject.eng	Alzheimer	de
dc.subject.eng	passive immunization	de
dc.subject.eng	NT4X	de
dc.subject.eng	Tg4-42	de
dc.subject.eng	CA1	de
dc.subject.eng	neuron loss	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0023-3E99-8-1
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	GOK-MEDIZIN	de
dc.description.embargoed	2017-07-11
dc.identifier.ppn	892892560

Dateien

Name:Dissertation_Henning_Borgers.pdf

Größe:1.942Mb

Format:PDF

Öffnen

Name:: Dissertation_Henning_Borgers.pdf
Größe:: 1.942Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2877]

Zur Kurzanzeige